Which has stronger earnings & valuation, NGEN or MNPR?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A -$31.58M -$0.46 N/A Monopar Therapeutics N/A N/A -$13.72M -$2.17 N/A

Is NGEN or MNPR more profitable?

Monopar Therapeutics' return on equity of -13.08% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Monopar Therapeutics N/A -13.08% -12.79%

Does the media refer more to NGEN or MNPR?

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.27 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NGEN or NGNE more profitable?

Neurogene's return on equity of -45.10% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Neurogene N/A -45.10% -41.00%

Does the media prefer NGEN or NGNE?

In the previous week, Neurogene had 2 more articles in the media than NervGen Pharma. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.34 beat Neurogene's score of 0.49 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurogene 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, SVA or NGEN?

NervGen Pharma has lower revenue, but higher earnings than Sinovac Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A NervGen Pharma N/A N/A -$31.58M -$0.46 N/A

Is SVA or NGEN more profitable?

Sinovac Biotech's return on equity of 0.00% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A NervGen Pharma N/A -1,259.82% -199.79%

Is NGEN or CBIO more profitable?

Crescent Biopharma's return on equity of -101.50% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Crescent Biopharma N/A -101.50% -86.86%

Does the media prefer NGEN or CBIO?

In the previous week, Crescent Biopharma had 28 more articles in the media than NervGen Pharma. MarketBeat recorded 29 mentions for Crescent Biopharma and 1 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.34 beat Crescent Biopharma's score of 0.30 indicating that NervGen Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Is VALN or NGEN more profitable?

NervGen Pharma has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Valneva -110.33% -153.20% -39.50% NervGen Pharma N/A -1,259.82% -199.79%

Does the media favor VALN or NGEN?

In the previous week, Valneva and Valneva both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Valneva's score of 0.27 indicating that NervGen Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NervGen Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NervGen Pharma (NGEN) Competitors

$1.96 -0.11 (-5.31%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.07 (+3.62%)

As of 04:10 AM Eastern

Compare

NGEN vs. MNPR, NGNE, SVA, CBIO, and VALN

Should you buy NervGen Pharma stock or one of its competitors? NervGen Pharma's main competitors and comparable companies include Monopar Therapeutics (MNPR), Neurogene (NGNE), Sinovac Biotech (SVA), Crescent Biopharma (CBIO), and Valneva (VALN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does NervGen Pharma compare to Monopar Therapeutics?

NervGen Pharma (NASDAQ:NGEN) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

In the previous week, NervGen Pharma and NervGen Pharma both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Monopar Therapeutics' score of 0.27 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monopar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.8% of Monopar Therapeutics shares are held by institutional investors. 5.8% of NervGen Pharma shares are held by company insiders. Comparatively, 9.7% of Monopar Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Monopar Therapeutics' return on equity of -13.08% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Monopar Therapeutics	N/A	-13.08%	-12.79%

Monopar Therapeutics is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Monopar Therapeutics	N/A	N/A	-$13.72M	-$2.17	N/A

NervGen Pharma currently has a consensus price target of $14.00, indicating a potential upside of 614.29%. Monopar Therapeutics has a consensus price target of $121.36, indicating a potential upside of 35.78%. Given NervGen Pharma's higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Monopar Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

Monopar Therapeutics beats NervGen Pharma on 7 of the 11 factors compared between the two stocks.

How does NervGen Pharma compare to Neurogene?

NervGen Pharma (NASDAQ:NGEN) and Neurogene (NASDAQ:NGNE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

NervGen Pharma has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than NervGen Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Neurogene	$930K	665.49	-$90.35M	-$5.03	N/A

NervGen Pharma currently has a consensus target price of $14.00, suggesting a potential upside of 614.29%. Neurogene has a consensus target price of $83.67, suggesting a potential upside of 170.50%. Given NervGen Pharma's higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Neurogene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Neurogene	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Neurogene had 2 more articles in the media than NervGen Pharma. MarketBeat recorded 3 mentions for Neurogene and 1 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.34 beat Neurogene's score of 0.49 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurogene	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene's return on equity of -45.10% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Neurogene	N/A	-45.10%	-41.00%

52.4% of Neurogene shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 11.7% of Neurogene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Neurogene beats NervGen Pharma on 7 of the 13 factors compared between the two stocks.

How does NervGen Pharma compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

NervGen Pharma has lower revenue, but higher earnings than Sinovac Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

In the previous week, NervGen Pharma had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 1 mentions for NervGen Pharma and 0 mentions for Sinovac Biotech. NervGen Pharma's average media sentiment score of 1.34 beat Sinovac Biotech's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Sinovac Biotech	Neutral
NervGen Pharma	Positive

Sinovac Biotech's return on equity of 0.00% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
NervGen Pharma	N/A	-1,259.82%	-199.79%

Sinovac Biotech currently has a consensus target price of $1.00, suggesting a potential downside of 84.54%. NervGen Pharma has a consensus target price of $14.00, suggesting a potential upside of 614.29%. Given NervGen Pharma's higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

Summary

NervGen Pharma beats Sinovac Biotech on 6 of the 10 factors compared between the two stocks.

How does NervGen Pharma compare to Crescent Biopharma?

NervGen Pharma (NASDAQ:NGEN) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, profitability, earnings, institutional ownership, analyst recommendations, risk and media sentiment.

Crescent Biopharma's return on equity of -101.50% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Crescent Biopharma	N/A	-101.50%	-86.86%

NervGen Pharma has higher earnings, but lower revenue than Crescent Biopharma. NervGen Pharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A
Crescent Biopharma	$11.88M	44.36	-$153.94M	-$6.72	N/A

NervGen Pharma presently has a consensus price target of $14.00, indicating a potential upside of 614.29%. Crescent Biopharma has a consensus price target of $29.60, indicating a potential upside of 108.60%. Given NervGen Pharma's higher possible upside, equities analysts plainly believe NervGen Pharma is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Crescent Biopharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

75.2% of Crescent Biopharma shares are owned by institutional investors. 5.8% of NervGen Pharma shares are owned by company insiders. Comparatively, 24.8% of Crescent Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Crescent Biopharma had 28 more articles in the media than NervGen Pharma. MarketBeat recorded 29 mentions for Crescent Biopharma and 1 mentions for NervGen Pharma. NervGen Pharma's average media sentiment score of 1.34 beat Crescent Biopharma's score of 0.30 indicating that NervGen Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Crescent Biopharma beats NervGen Pharma on 7 of the 11 factors compared between the two stocks.

How does NervGen Pharma compare to Valneva?

Valneva (NASDAQ:VALN) and NervGen Pharma (NASDAQ:NGEN) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

In the previous week, Valneva and Valneva both had 1 articles in the media. NervGen Pharma's average media sentiment score of 1.34 beat Valneva's score of 0.27 indicating that NervGen Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NervGen Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.4% of Valneva shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valneva presently has a consensus price target of $9.30, suggesting a potential upside of 46.46%. NervGen Pharma has a consensus price target of $14.00, suggesting a potential upside of 614.29%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83

NervGen Pharma has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
NervGen Pharma	N/A	-1,259.82%	-199.79%

NervGen Pharma has lower revenue, but higher earnings than Valneva. NervGen Pharma is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$197.56M	3.05	-$130.33M	-$2.11	N/A
NervGen Pharma	N/A	N/A	-$31.58M	-$0.46	N/A

Summary

NervGen Pharma beats Valneva on 8 of the 14 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$166.50M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-4.26	13.88	274.07	25.69
Price / Sales	N/A	1,356.95	643.13	79.17
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	65.33	15.40	10.47	6.32
Net Income	-$31.58M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-13.66%	-1.71%	-0.67%	0.17%
1 Month Performance	-2.00%	-6.18%	-3.17%	-3.27%
1 Year Performance	N/A	30.64%	15.13%	5.58%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	2.0265 of 5 stars	$1.96 -5.3%	$14.00 +614.3%	N/A	$166.50M	N/A	N/A	8
MNPR Monopar Therapeutics	2.5209 of 5 stars	$96.62 -5.9%	$120.08 +24.3%	+32.1%	$651.87M	N/A	N/A	22	News Coverage
NGNE Neurogene	2.4129 of 5 stars	$32.75 +1.0%	$83.67 +155.5%	+83.6%	$648.26M	N/A	N/A	131
SVA Sinovac Biotech	0.9139 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.67M	$386.01M	N/A	3,008	High Trading Volume
CBIO Crescent Biopharma	3.1025 of 5 stars	$17.15 +2.3%	$29.60 +72.6%	+9.6%	$635.72M	$11.88M	N/A	44

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. MNPR, NGNE, SVA, CBIO, and VALN

How does NervGen Pharma compare to Monopar Therapeutics?

Summary

How does NervGen Pharma compare to Neurogene?

Summary

How does NervGen Pharma compare to Sinovac Biotech?

Summary

How does NervGen Pharma compare to Crescent Biopharma?

Summary

How does NervGen Pharma compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. MNPR, NGNE, SVA, CBIO, and VALN

How does NervGen Pharma compare to Monopar Therapeutics?

Does the media refer more to NGEN or MNPR?

Do insiders & institutionals have more ownership in NGEN or MNPR?

Is NGEN or MNPR more profitable?

Which has stronger earnings & valuation, NGEN or MNPR?

Do analysts prefer NGEN or MNPR?

Summary

How does NervGen Pharma compare to Neurogene?

Which has better earnings and valuation, NGEN or NGNE?

Do analysts recommend NGEN or NGNE?

Does the media prefer NGEN or NGNE?

Is NGEN or NGNE more profitable?

Do institutionals & insiders hold more shares of NGEN or NGNE?

Summary

How does NervGen Pharma compare to Sinovac Biotech?

Which has better earnings & valuation, SVA or NGEN?

Does the media prefer SVA or NGEN?

Is SVA or NGEN more profitable?

Do analysts rate SVA or NGEN?

Summary

How does NervGen Pharma compare to Crescent Biopharma?

Is NGEN or CBIO more profitable?

Which has preferable earnings & valuation, NGEN or CBIO?

Do analysts rate NGEN or CBIO?

Do institutionals & insiders believe in NGEN or CBIO?

Does the media prefer NGEN or CBIO?

Summary

How does NervGen Pharma compare to Valneva?

Does the media favor VALN or NGEN?

Do institutionals and insiders hold more shares of VALN or NGEN?

Do analysts rate VALN or NGEN?

Is VALN or NGEN more profitable?

Which has higher valuation & earnings, VALN or NGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools